Latest news
News
-
2 November 2018
Top Ten Psoriasis Research Priorities Announced
The 'Top Ten' list, agreed upon by patients, carers and clinicians marks the culmination of the psoriasis Priority Setting Partnership (PSP).
-
16 October 2018
Humira (Adalimumab) - Most Commonly Prescribed Biologic for Psoriasis Comes Off Patent
AbbVie's Humira (Adalimumab) comes off patent, paving the way for 'biosimilar' products to be offered on the NHS.
-
8 October 2018
Taltz (Ixekizumab) - New Psoriatic Arthritis Treatment Approved in Scotland
Taltz (Ixekizumab) is accepted by the SMC for the treatment of psoriatic arthritis in adults in Scotland.
-
3 October 2018
Xeljanz (Tofacitinib) - First-of-its-kind Treatment Approved for Psoriatic Arthritis
NICE approves Xeljanz (Tofacitinib) for the treatment of psoriatic arthritis in adults in England and Wales.
-
4 September 2018
APRICOT Trial Protocol Published
The open access paper provides details of the study, which is testing a potential new treatment for Palmo-Plantar Pustulosis (PPP).